Ventyx Biosciences, Inc. $VTYX Shares Sold by Cibc World Market Inc.

Cibc World Market Inc. lessened its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 39.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 155,250 shares of the company’s stock after selling 99,750 shares during the period. Cibc World Market Inc.’s holdings in Ventyx Biosciences were worth $483,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Citizens Financial Group Inc. RI purchased a new position in Ventyx Biosciences in the third quarter valued at approximately $442,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Ventyx Biosciences in the second quarter worth $71,000. Affinity Asset Advisors LLC purchased a new position in shares of Ventyx Biosciences in the 2nd quarter valued at $9,707,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Ventyx Biosciences by 8.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock valued at $2,023,000 after acquiring an additional 73,601 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Ventyx Biosciences during the 2nd quarter valued at $148,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on VTYX. UBS Group reissued a “neutral” rating and issued a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a research report on Thursday, January 8th. HC Wainwright lowered Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price for the company. in a research note on Thursday, January 8th. Wells Fargo & Company reiterated an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. Lifesci Capital restated a “market perform” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Clear Str downgraded shares of Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 7th. Eight research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ventyx Biosciences presently has an average rating of “Reduce” and a consensus price target of $14.00.

Insider Buying and Selling

In other Ventyx Biosciences news, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This represents a 1.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Nuss sold 12,675 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the sale, the insider directly owned 489,481 shares of the company’s stock, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 14.49% of the company’s stock.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX opened at $13.96 on Thursday. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -9.31 and a beta of 1.25. Ventyx Biosciences, Inc. has a one year low of $0.78 and a one year high of $25.00. The business’s 50-day simple moving average is $11.94 and its 200 day simple moving average is $7.51.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.